文献速递心力衰竭与心肌病瓣膜病与结构性心脏病

Acoramidis 对野生型与变异型转甲状腺素蛋白淀粉样心肌病的疗效

Efficacy of Acoramidis in Wild-Type and Variant Transthyretin Amyloid Cardiomyopathy: Results From ATTRibute-CM and Its Open-Label Extension.
PubMed 文献 · JAMA Cardiol · 2026-01-01

基于 ATTRibute-CM Ⅲ期随机安慰剂对照试验及其开放标签扩展(OLE),纳入 611 例改良意向治疗人群,评估口服 Acoramidis 712 mg 每日两次在野生型与变异型 ATTR-CM 中的疗效。30 个月时野生型与变异型患者的全因死亡/首次心血管住院风险分别降低 31% 与 59%,至 42 个月全因死亡获益持续,各变异亚组结果一致。

要点

  • Acoramidis 在野生型与变异型 ATTR-CM 中均显示一致疗效。
  • 30 个月时 ATTRwt-CM 的 ACM/首次 CVH 风险降低 31%(HR 0.69)。
  • 30 个月时 ATTRv-CM 的 ACM/首次 CVH 风险降低 59%(HR 0.41)。

核心结论

  • Acoramidis 在 ATTRwt-CM 与 ATTRv-CM 中均观察到一致获益。
  • 这些结果为假设生成性,变异亚组的治疗获益仍需进一步研究。

研究设计与样本

  • 国际多中心Ⅲ期随机安慰剂对照研究,2019 年 4 月至 2023 年 5 月,OLE 随访至 42 个月。
  • ATTRibute-CM 入组 632 例 ATTR-CM 患者,611 例纳入改良意向治疗人群,380 例进入 OLE。
  • 随机接受口服 Acoramidis 712 mg 或安慰剂每日两次共 30 个月,随后 12 个月开放标签治疗。

主要发现

  • 30 个月时 ACM/首次 CVH:ATTRwt-CM 的 HR 0.69(95%CI 0.52-0.90;P=.007),ATTRv-CM 的 HR 0.41(95%CI 0.21-0.81;P=.01)。
  • 至 42 个月 ACM:ATTRwt-CM 的 HR 0.70(95%CI 0.50-0.98;P=.04),ATTRv-CM 的 HR 0.41(95%CI 0.19-0.93;P=.03)。
  • 次要终点在 ATTRwt-CM 与 ATTRv-CM 中均观察到一致的治疗获益。
  • 变异亚组(p.Val142Ile 与非 p.Val142Ile)在 30 个月 ACM/CVH 与 42 个月 ACM 上获益一致。

临床怎么用

  • 对野生型与变异型 ATTR-CM 患者,Acoramidis 可考虑用于降低死亡与心血管住院风险。
  • 变异亚组数据为假设生成性,个体化决策时需结合具体变异类型与病情。

局限性

  • 变异型 ATTR-CM 样本量较小,仅 59 例,其中 p.Val142Ile 35 例。
  • 变异亚组分析为事后分析,结果需进一步研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Transthyretin amyloid cardiomyopathy (ATTR-CM), a progressive disease caused by misfolded transthyretin (TTR), occurs as wild-type (ATTRwt-CM) or variant (ATTRv-CM) forms. p.Val142Ile is the most common variant in the US, linked to rapid progression and increased mortality. Acoramidis achieves near-complete (≥90%) TTR stabilization and showed clinical benefit in the 30-month ATTRibute-CM trial and through month 42 in the ongoing open-label extension (OLE). OBJECTIVE: To evaluate the efficacy of acoramidis in ATTRwt-CM, ATTRv-CM, and variant subgroups (p.Val142Ile and non-p.Val142Ile). DESIGN, SETTING, AND PARTICIPANTS: This international, multicenter, phase 3, randomized placebo-controlled study took place from April 2019 to May 2023 with ongoing OLE (month 42). ATTRibute-CM enrolled 632 participants with ATTR-CM; 611 of 632 were included in the modified intention-to-treat (mITT) population. There were 380 participants who continued into the OLE. These data were analyzed from January 2025 to July 2025. INTERVENTIONS: Oral acoramidis, 712 mg, or placebo twice daily for 30 months, followed by 12 months of open-label treatment. MAIN OUTCOMES AND MEASURES: All-cause mortality (ACM), cardiovascular-related hospitalizations (CVH), serum TTR, 6-minute walk distance, Kansas City Cardiomyopathy Questionnaire Overall Summary score, and N-terminal pro B-type natriuretic peptide in participants with ATTRwt-CM and ATTRv-CM. Post-hoc analyses were conducted in variant subgroups, including p.Val142Ile. RESULTS: Overall, 552 participants with wild-type ATTR-CM (mean [SD] age, 78 [6.3] years; 92.0% male and 8.0% female) and 59 participants with variant ATTR-CM (mean [SD] age, 73 [7.7] years; 77.3% male and 22.7% female) were randomized (mITT population), including 35 with p.Val142Ile. Consistent efficacy was observed in wild-type and variant subgroups for ACM/CVH through month 30 and ACM through month 42. At month 30, acoramidis reduced the risk of ACM/first CVH vs placebo by 31% in ATTRwt-CM (hazard ratio [HR], 0.69; 95% CI, 0.52-0.90; P = .007) and by 59% in ATTRv-CM (HR, 0.41; 95% CI, 0.21-0.81; P = .01). ACM was reduced through month 42 with HRs of 0.70 (95% CI, 0.50-0.98; P = .04) and 0.41 (95% CI, 0.19-0.93; P = .03) in the ATTRwt-CM and ATTRv-CM groups, respectively. Consistent treatment benefit was observed in participants with ATTRwt-CM and ATTRv-CM for secondary end points. Within variant subgroups (p.Val142Ile vs non-p.Val142Ile), consistent treatment benefits were observed for ACM/CVH through month 30 and ACM through month 42. CONCLUSIONS AND RELEVANCE: The beneficial effect of acoramidis was observed consistently in ATTRwt-CM and ATTRv-CM groups. These hypothesis-generating results indicate that further studies are warranted to better characterize the therapeutic benefit of acoramidis in variant subgroups. TRIAL REGISTRATION: ClinicalTrials.gov Identifiers: NCT03860935; NCT04988386.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Alexander KM, Davis MK, Akinboboye O, et al. Efficacy of Acoramidis in Wild-Type and Variant Transthyretin Amyloid Cardiomyopathy: Results From ATTRibute-CM and Its Open-Label Extension. JAMA Cardiol. 2026. PMID: 41205147. doi:10.1001/jamacardio.2025.4477

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。